Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer, Annals of Oncology, vol.24, issue.5, pp.1267-1273, 2013. ,
DOI : 10.1093/annonc/mds620
Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011. ,
DOI : 10.3322/caac.20107
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.19, issue.3, pp.508-515, 2008. ,
DOI : 10.1093/annonc/mdm496
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1166-1169, 2007. ,
DOI : 10.1093/jnci/92.3.205
Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007. ,
DOI : 10.1200/JCO.2006.10.5437
Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3, pp.374-379, 2008. ,
DOI : 10.1200/JCO.2007.12.5906
URL : https://hal.archives-ouvertes.fr/hal-00363737
Mutations in Colorectal Cancer, New England Journal of Medicine, vol.369, issue.11, pp.1023-1034, 2013. ,
DOI : 10.1056/NEJMoa1305275
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized controlled trials, Ann Oncol, 2014. ,
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and metaanalysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations, Lancet Oncol. Crit Rev Oncol Hematol, vol.9, issue.85, pp.962-972, 2008. ,
Metastatic Colon Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5924-5930, 2009. ,
DOI : 10.1200/JCO.2008.21.6796
URL : https://hal.archives-ouvertes.fr/hal-00618089
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer, International Journal of Cancer, vol.67, issue.6 ,
DOI : 10.1002/ijc.25152
Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer, Clinical Chemistry, vol.55, issue.7, pp.1327-1336, 2009. ,
DOI : 10.1373/clinchem.2008.116632
MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, Statistics in Medicine, vol.15, issue.4, pp.361-387, 1996. ,
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
A bootstrap resampling procedure for model building: Application to the cox regression model, Statistics in Medicine, vol.42, issue.16, pp.2093-2109, 1992. ,
DOI : 10.1002/sim.4780111607
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials, European Journal of Cancer, vol.48, issue.10, pp.1466-1475, 2012. ,
DOI : 10.1016/j.ejca.2012.02.057
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study, Anticancer Res, vol.34, pp.1967-1973, 2014. ,
Mutant ras proteins and cell transformation, Nature, vol.310, issue.5979, pp.628-629, 1984. ,
DOI : 10.1038/310628a0
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab, Journal of Cancer Research and Clinical Oncology, vol.351, issue.4, pp.737-748, 2014. ,
DOI : 10.1158/0008-5472
Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab, Journal of Translational Medicine, vol.10, issue.1, pp.1479-5876, 2012. ,
DOI : 10.1245/s10434-009-0864-z
Activation of the Serine/Threonine Protein Kinase AKT During the Progression of Colorectal Neoplasia, Clinical Colorectal Cancer, vol.6, issue.9, pp.652-656, 2007. ,
DOI : 10.3816/CCC.2007.n.034
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, The Lancet Oncology, vol.12, issue.6, pp.594-603, 2011. ,
DOI : 10.1016/S1470-2045(10)70209-6
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer, World Journal of Gastroenterology, vol.20, issue.29, pp.9862-9871, 2014. ,
DOI : 10.3748/wjg.v20.i29.9862
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer, BMC Cancer, vol.20, issue.11, pp.1471-2407, 2014. ,
DOI : 10.1093/emboj/20.11.2723
La Situation du Cancer en France en 2012, 2012. ,
The Hallmarks of Cancer, Cell, vol.100, issue.1, pp.57-70, 2000. ,
DOI : 10.1016/S0092-8674(00)81683-9
Hallmarks of Cancer: The Next Generation, Cell, vol.144, issue.5, pp.646-74, 2011. ,
DOI : 10.1016/j.cell.2011.02.013
Mutant ras proteins and cell transformation, Nature, vol.310, issue.5979, pp.628-637, 1984. ,
DOI : 10.1038/310628a0
Tumorigenic transformation of mammalian cells induced by a normal human gene homologous to the oncogene of Harvey murine sarcoma virus, Nature, vol.31, issue.5866 ,
DOI : 10.1038/297479a0
Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab, Journal of Clinical Oncology, vol.26, issue.3 ,
DOI : 10.1200/JCO.2007.12.5906
URL : https://hal.archives-ouvertes.fr/hal-00363737
Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer patients. Presented at: European Cancer Congress 2013 The Netherlands, 2013. ,
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, The Lancet Oncology, vol.11, issue.8, pp.753-62, 2010. ,
DOI : 10.1016/S1470-2045(10)70130-3
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a 19 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, Lancet, vol.355, issue.9209, pp.1041-1048, 2000. ,
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, Journal of Clinical Oncology, vol.22, issue.2 ,
DOI : 10.1200/JCO.2004.05.113
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial, The Lancet, vol.370, issue.9582, pp.143-52, 2007. ,
DOI : 10.1016/S0140-6736(07)61087-3
Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell???Italia Meridionale, Journal of Clinical Oncology, vol.23, issue.22, pp.4866-75, 2005. ,
DOI : 10.1200/JCO.2005.07.113
Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest, Journal of Clinical Oncology, vol.25, issue.13, pp.1670-1676, 2007. ,
DOI : 10.1200/JCO.2006.09.0928
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG), British Journal of Cancer, vol.16, issue.6, pp.798-805, 2006. ,
DOI : 10.1200/JCO.2004.05.113
Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases, Cancer Chemotherapy and Pharmacology, vol.23, issue.6, pp.195-201, 2008. ,
DOI : 10.1007/s00280-007-0588-3
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study, Journal of Clinical Oncology, vol.28, issue.31, pp.4697-705, 2010. ,
DOI : 10.1200/JCO.2009.27.4860
and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis, Acta Oncologica, vol.31, issue.7, pp.852-64, 2014. ,
DOI : 10.1002/ijc.28153
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer, Annals of Oncology, vol.25, issue.7, pp.1346-55, 2014. ,
DOI : 10.1093/annonc/mdu141
Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer, J Clin Oncol, vol.32, issue.21, pp.2240-2247, 2014. ,
Cetuximab for the Treatment of Colorectal Cancer, New England Journal of Medicine, vol.357, issue.20, pp.2040-2048, 2007. ,
DOI : 10.1056/NEJMoa071834
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.360, issue.14, pp.1408-1425, 2009. ,
DOI : 10.1056/NEJMoa0805019
Mutation Status, Journal of Clinical Oncology, vol.29, issue.15, pp.2011-2020, 2011. ,
DOI : 10.1200/JCO.2010.33.5091
leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer, J Clin Oncol, vol.27, issue.5, pp.663-71, 2009. ,
Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study, Annals of Oncology, vol.22, issue.7, pp.1535-1581, 2011. ,
DOI : 10.1093/annonc/mdq632
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials, European Journal of Cancer, vol.48, issue.10, pp.1466-75, 2012. ,
DOI : 10.1016/j.ejca.2012.02.057
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial, The Lancet Oncology, vol.14, issue.1 ,
DOI : 10.1016/S1470-2045(12)70477-1
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy, p.18147 ,
FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials, Clinical Colorectal Cancer, vol.12, issue.3, pp.145-51, 2013. ,
DOI : 10.1016/j.clcc.2013.04.006
FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer, Oncology, vol.87, issue.3, pp.148-58, 2014. ,
DOI : 10.1159/000361031
Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen, Journal of Clinical Oncology, vol.30, issue.28 ,
DOI : 10.1200/JCO.2012.42.8201
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial, The Lancet, vol.381, issue.9863, pp.303-315, 2013. ,
DOI : 10.1016/S0140-6736(12)61900-X
CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC)., Journal of Clinical Oncology, vol.32, issue.18_suppl ,
DOI : 10.1200/jco.2014.32.18_suppl.lba3
Oncogenic kinase signalling, 2014 ASCO Annual Meeting, pp.355-65, 2001. ,
The HER family and cancer: emerging molecular mechanisms and therapeutic targets, Trends in Molecular Medicine, vol.13, issue.12, pp.527-561, 2007. ,
DOI : 10.1016/j.molmed.2007.10.002
Growth factors of the EGF family and their receptors], Bull Cancer, vol.94, issue.7, 2007. ,
Autocrine, paracrine and juxtacrine signaling by EGFR ligands, Cellular Signalling, vol.17, issue.10, pp.1183-93, 2005. ,
DOI : 10.1016/j.cellsig.2005.03.026
Timeline: The discovery of receptor tyrosine kinases: targets for cancer therapy, Nature Reviews Cancer, vol.4, issue.5, pp.361-70, 2004. ,
DOI : 10.1038/nrc1360
Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy, Differentiation, vol.75, issue.9, pp.788-99, 2007. ,
DOI : 10.1111/j.1432-0436.2007.00200.x
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC, Nature Reviews Clinical Oncology, vol.58, issue.6, pp.352-66, 2009. ,
DOI : 10.1038/nrclinonc.2009.62
Anti-EGFR Therapy: Mechanism and Advances in Clinical Efficacy in Breast Cancer, Journal of Oncology, vol.14, issue.3, p.526963, 2009. ,
DOI : 10.1038/sj.onc.1208774
Epidermal Growth Factor Receptor Targeting in Cancer, Seminars in Oncology, vol.33, issue.4, pp.369-85, 2006. ,
DOI : 10.1053/j.seminoncol.2006.04.003
Amplification of the epidermal growth factor receptor gene in glioblastoma: An analysis of the relationship between genotype and phenotype by CISH method, Neuropathology, vol.65, issue.2 ,
DOI : 10.1007/BF00196514
Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin, Nature, vol.4, issue.5998, pp.144-151, 1985. ,
DOI : 10.1038/313144a0
Epidermal growth factor receptors in non-small cell lung cancer, British Journal of Cancer, vol.55, issue.5, pp.513-519, 1987. ,
DOI : 10.1038/bjc.1987.104
Epidermal Growth Factor Receptor and Epidermal Growth Factor Receptor Variant III Gene Expression in Metastatic Colorectal Cancer, Clinical Colorectal Cancer, vol.6, issue.3, pp.214-222, 2006. ,
DOI : 10.3816/CCC.2006.n.038
Lack of the type III epidermal growth factor receptor mutation in colorectal cancer, Anticancer Res, vol.26, issue.6C, pp.4889-93, 2006. ,
STAT3 and epithelial-mesenchymal transitions in carcinomas):e28975. 63 Targeting EGFR and VEGF(R) pathway crosstalk in tumor survival and angiogenesis, Jakstat. Pharmacol Ther, vol.3131, issue.11, pp.80-90, 2011. ,
MET-Mediated Resistance to EGFR Inhibitors: An Old Liaison Rooted in Colorectal Cancer Stem Cells, Cancer Research, vol.74, issue.14, pp.3647-51, 2014. ,
DOI : 10.1158/0008-5472.CAN-14-1088
Survival of Cancer Cells Is Maintained by EGFR Independent of Its Kinase Activity, Cancer Cell, vol.13, issue.5, pp.385-93, 2008. ,
DOI : 10.1016/j.ccr.2008.03.015
Signal transduction by epidermal growth factor occurs through the subclass of high affinity receptors, The Journal of Cell Biology, vol.109, issue.5, pp.2495-507, 1989. ,
DOI : 10.1083/jcb.109.5.2495
On the nature of low- and high-affinity EGF receptors on living cells, Proceedings of the National Academy of Sciences, vol.103, issue.15, pp.5735-5775, 2006. ,
DOI : 10.1073/pnas.0601469103
High-affinity Binding of Epidermal Growth Factor (EGF) to EGF Receptor Is Disrupted by Overexpression of Mutant Dynamin (K44A), Journal of Biological Chemistry, vol.273, issue.27, pp.16639-16681, 1998. ,
DOI : 10.1074/jbc.273.27.16639
High-and low-affinity epidermal growth factor receptorligand interactions activate distinct signaling pathways Single-molecule imaging of EGFR signalling on the surface of living cells, PLoS One. Nat Cell Biol, vol.62, issue.13, pp.168-72, 2000. ,
Nuclear trafficking of the epidermal growth factor receptor family membrane proteins, Oncogene, vol.18, issue.28, pp.3997-4006, 2010. ,
DOI : 10.1042/BST0361373
Landscape of EGFR signaling network in human cancers: Biology and therapeutic response in relation to receptor subcellular locations, Cancer Letters, vol.318, issue.2, pp.124-158, 2012. ,
DOI : 10.1016/j.canlet.2012.01.011
The Translocon Sec61?? Localized in the Inner Nuclear Membrane Transports Membrane-embedded EGF Receptor to the Nucleus, Journal of Biological Chemistry, vol.285, issue.49, pp.38720-38729, 2010. ,
DOI : 10.1074/jbc.M110.158659
Epidermal growth factor receptor transactivation is required for proteinase-activated receptor-2-induced COX ,
Nuclear localization of EGF receptor and its potential new role as a transcription factor, Nature Cell Biology, vol.3, issue.9, pp.802-810, 2001. ,
DOI : 10.1038/ncb0901-802
Nuclear EGFR as a molecular target in cancer, Radiotherapy and Oncology, vol.108, issue.3, pp.370-377, 2013. ,
DOI : 10.1016/j.radonc.2013.06.010
Nuclear Translocation of Epidermal Growth Factor Receptor by Akt-dependent Phosphorylation Enhances Breast Cancer-resistant Protein Expression in Gefitinib-resistant Cells, Journal of Biological Chemistry, vol.286, issue.23, pp.20558-68, 2011. ,
DOI : 10.1074/jbc.M111.240796
Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity, Radiotherapy and Oncology, vol.76, issue.2, pp.157-61, 2005. ,
DOI : 10.1016/j.radonc.2005.06.022
EGFR Nuclear Translocation Modulates DNA Repair following Cisplatin and Ionizing Radiation Treatment, Cancer Research, vol.71, issue.3, pp.1103-1117, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-2384
Nuclear EGFR contributes to acquired resistance to cetuximab, Oncogene, vol.8, issue.43, pp.3801-3814, 2009. ,
DOI : 10.1038/35052073
Nuclear EGFR is required for cisplatin resistance and DNA repair Erlotinib in previously treated non-small-cell lung cancer, Am J Transl Res. N Engl J Med, vol.1353, issue.822, pp.249-58123, 2005. ,
Gefitinib or Carboplatin???Paclitaxel in Pulmonary Adenocarcinoma, New England Journal of Medicine, vol.361, issue.10, pp.947-57, 2009. ,
DOI : 10.1056/NEJMoa0810699
Targeting ErbB receptors in breast cancer]. Bull Cancer, pp.147-70, 2007. ,
Oncogene, Growth Factors, vol.26, issue.3, pp.233-275, 1991. ,
DOI : 10.1083/jcb.102.6.2211
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study, The Lancet Oncology, vol.14, issue.6, pp.461-71, 2013. ,
DOI : 10.1016/S1470-2045(13)70130-X
in solid tumors: more than 10 years under the microscope; where are we now?, Future Oncology, vol.10, issue.8, pp.1469-86, 2014. ,
DOI : 10.2217/fon.14.19
HER2 and lung cancer, Expert Review of Anticancer Therapy, vol.13, issue.10, pp.1219-1247, 2013. ,
DOI : 10.1586/14737140.2013.846830
Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer, Cancer Biomarkers, vol.11, issue.5, pp.219-245, 2012. ,
DOI : 10.3233/CBM-2012-00282
A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer, Cancer Discovery, vol.1, issue.6, pp.508-531, 2011. ,
DOI : 10.1158/2159-8290.CD-11-0109
Marked response to single agent trastuzumab in a patient with metastatic ,
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics, Seminars in Cell & Developmental Biology, vol.21, issue.9, pp.944-50, 2010. ,
DOI : 10.1016/j.semcdb.2010.08.007
The upgraded role of HER3 and HER4 receptors in breast cancer, Critical Reviews in Oncology/Hematology, vol.74, issue.2, pp.73-81, 2010. ,
DOI : 10.1016/j.critrevonc.2009.04.011
Her4 mediates liganddependent antiproliferative and differentiation responses in human breast cancer cells The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells, Mol Cell Biol. Cancer Res, vol.2166, issue.1312, pp.4265-756412, 2001. ,
ERBB4 Mutation Analysis: Emerging Molecular Target for Melanoma Treatment, Methods Mol Biol, vol.1102, pp.461-80, 2014. ,
DOI : 10.1007/978-1-62703-727-3_24
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5125540
ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases ,
kinase domain in human cancers, International Journal of Cancer, vol.62, issue.6, pp.1426-1435, 2006. ,
DOI : 10.1002/ijc.21507
A Novel Polymorphism in the Promoter Region of ERBB4 Is Associated with Breast and Colorectal Cancer Risk, Clinical Cancer Research, vol.13, issue.24 ,
DOI : 10.1158/1078-0432.CCR-07-0457
The Ras superfamily at a glance, Journal of Cell Science, vol.118, issue.5, pp.843-849, 2005. ,
DOI : 10.1242/jcs.01660
Targeting the Mitogen-Activated Protein Kinase Pathway: Physiological Feedback and Drug Response, Clinical Cancer Research, vol.16, issue.13, pp.3329-3363, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-3064
UCSF Chimera?A visualization system for exploratory research and analysis, Journal of Computational Chemistry, vol.373, issue.13, pp.1605-1617, 2004. ,
DOI : 10.1002/jcc.20084
Targeting PI3K signalling in cancer: opportunities, challenges and limitations, Nature Reviews Cancer, vol.16, issue.8 ,
DOI : 10.1038/nrc2664
PI3K/PTEN signaling in tumorigenesis and angiogenesis, Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, vol.1784, issue.1, pp.19-65, 2009. ,
DOI : 10.1016/j.bbapap.2007.09.008
Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting, Adv Cancer Res, vol.94, pp.29-86, 2005. ,
DOI : 10.1016/S0065-230X(05)94002-5
Ras family genes: An interesting link between cell cycle and cancer, Journal of Cellular Physiology, vol.139, issue.2, pp.125-155, 2002. ,
DOI : 10.1002/jcp.10109
Impact of KRAS in standard treatment of non-small cell lung cancer (NSCLC) patients in 2009: prognostic and predictive value], Bull Cancer, vol.96, pp.57-68, 2009. ,
Technical considerations for KRAS testing in colorectal cancer. The pathologist's point of view], Bull Cancer, vol.96, pp.15-22, 2009. ,
Raf: A Strategic Target for Therapeutic Development Against Cancer, Journal of Clinical Oncology, vol.23, issue.27, pp.6771-90, 2005. ,
DOI : 10.1200/JCO.2005.08.036
The RAF proteins take centre stage, Nature Reviews Molecular Cell Biology, vol.9, issue.11, pp.875-85, 2004. ,
DOI : 10.1096/fj.02-1096com
Therapeutic strategies for inhibiting oncogenic BRAF signaling, Current Opinion in Pharmacology, vol.8, issue.4, pp.419-445, 2008. ,
DOI : 10.1016/j.coph.2008.06.014
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation, New England Journal of Medicine, vol.364, issue.26, pp.2507-2523, 2011. ,
DOI : 10.1056/NEJMoa1103782
Mutation of the PIK3CA oncogene in human cancers, British Journal of Cancer, vol.14, issue.4, pp.455-464, 2006. ,
DOI : 10.1016/j.ceb.2005.02.011
Oncogenic Mutations of PIK3CA in Human Cancers, Cell Cycle, vol.3, issue.10, pp.1221-1225, 2004. ,
DOI : 10.4161/cc.3.10.1164
PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal Antibodies, Cancer Research, vol.69, issue.5, pp.1851-1858, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-2466
PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal Cancer, Clinical Cancer Research, vol.15, issue.9, pp.3184-3192, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-2961
Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab, European Journal of Cancer, vol.46, issue.11, pp.1997-2009, 1997. ,
DOI : 10.1016/j.ejca.2010.03.036
Mutations of KRAS and PIK3CA as independent predictors of distant metastases in colorectal cancer, Medical Oncology, vol.18, issue.8, pp.14-0016, 2014. ,
DOI : 10.1007/s12032-014-0016-6
Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience, PLoS ONE, vol.12, issue.7, p.68945, 2013. ,
DOI : 10.1371/journal.pone.0068945.s002
URL : https://hal.archives-ouvertes.fr/hal-00974911
[Method validation according to ISO 15189 and SH GTA 04: application for the detection of KRAS mutations using PCR TaqMan assay], Ann Biol Clin, vol.71, issue.5, pp.603-610, 2013. ,
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer, Annals of Oncology, vol.24, issue.5, pp.1267-73, 2013. ,
DOI : 10.1093/annonc/mds620
[Clinical, diagnostic significance and theranostic interest of PIK3CA gene mutations in breast cancer], Bull Cancer, vol.100, issue.10, pp.947-54, 2013. ,
Global cancer statistics, CA: A Cancer Journal for Clinicians, vol.82, issue.19 suppl, pp.69-90, 2011. ,
DOI : 10.3322/caac.20107
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab, Annals of Oncology, vol.19, issue.3, pp.508-523, 2008. ,
DOI : 10.1093/annonc/mdm496
Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab, Journal of Clinical Oncology, vol.25, issue.22, pp.3230-3237, 2007. ,
DOI : 10.1200/JCO.2006.10.5437
Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations, Critical Reviews in Oncology/Hematology, vol.85, issue.1, pp.45-81, 2013. ,
DOI : 10.1016/j.critrevonc.2012.05.001
Metastatic Colon Cancer, Journal of Clinical Oncology, vol.27, issue.35, pp.5924-5954, 2009. ,
DOI : 10.1200/JCO.2008.21.6796
URL : https://hal.archives-ouvertes.fr/hal-00618089
Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer, International Journal of Cancer, vol.67, issue.6, pp.1321-1352, 2010. ,
DOI : 10.1002/ijc.25152
Validation of a Phosphoprotein Array Assay for Characterization of Human Tyrosine Kinase Receptor Downstream Signaling in Breast Cancer, Clinical Chemistry, vol.55, issue.7, pp.1327-1363, 2009. ,
DOI : 10.1373/clinchem.2008.116632
MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS, Statistics in Medicine, vol.15, issue.4, pp.361-87, 1996. ,
DOI : 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
A bootstrap resampling procedure for model building: Application to the cox regression model, Statistics in Medicine, vol.42, issue.16, pp.2093-109, 1992. ,
DOI : 10.1002/sim.4780111607
Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study, Anticancer Res, vol.34, issue.4, pp.1967-73, 2014. ,
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab, Journal of Cancer Research and Clinical Oncology, vol.351, issue.4, pp.737-785, 2014. ,
DOI : 10.1158/0008-5472
Basal Subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase Feedback Signaling Determine Susceptibility of Breast Cancer Cells to MEK Inhibition, Cancer Research, vol.69, issue.2, pp.565-72, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-3389
Activation of the Serine/Threonine Protein Kinase AKT During the Progression of Colorectal Neoplasia, Clinical Colorectal Cancer, vol.6, issue.9, pp.652-658, 2007. ,
DOI : 10.3816/CCC.2007.n.034
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer, The Lancet Oncology, vol.12, issue.6, pp.594-603, 2011. ,
DOI : 10.1016/S1470-2045(10)70209-6
Strategies to overcome resistance to epidermal growth factor receptor monoclonal antibody therapy in metastatic colorectal cancer, World Journal of Gastroenterology, vol.20, issue.29, pp.9862-71, 2014. ,
DOI : 10.3748/wjg.v20.i29.9862
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer, BMC Cancer, vol.20, issue.11, pp.1471-2407, 2014. ,
DOI : 10.1093/emboj/20.11.2723
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2260-70, 2010. ,
DOI : 10.1056/NEJMoa1002315
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia, New England Journal of Medicine, vol.362, issue.24, pp.2251-2260, 2010. ,
DOI : 10.1056/NEJMoa0912614
The Efficacy and Safety of EGFR Inhibitor Monotherapy in Non-Small Cell Lung Cancer: A Systematic Review, Current Oncology Reports, vol.50, issue.4, pp.14-0390, 2014. ,
DOI : 10.1007/s11912-014-0390-4
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations, New England Journal of Medicine, vol.367, issue.18, pp.1694-703, 2012. ,
DOI : 10.1056/NEJMoa1210093
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer, New England Journal of Medicine, vol.367, issue.19, pp.1783-91, 2012. ,
DOI : 10.1056/NEJMoa1209124
CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy, Cancer Chemotherapy and Pharmacology, vol.104, issue.9783, pp.409-425, 2014. ,
DOI : 10.1007/s00280-013-2367-7
Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab, Clinical Cancer Research, vol.19, issue.4, pp.929-966, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2535
Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis, World Journal of Surgical Oncology, vol.11, issue.1, pp.1477-7819, 2013. ,
DOI : 10.1200/JCO.2008.16.1612
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer, World Journal of Gastroenterology, vol.20, issue.33, pp.11727-11762, 2014. ,
DOI : 10.3748/wjg.v20.i33.11727
Epidermal Growth Factor-like Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer, Molecular Cancer Therapeutics, vol.13, issue.9, pp.2238-2283, 2014. ,
DOI : 10.1158/1535-7163.MCT-14-0131
Tumor Heterogeneity Confounds and Illuminates: A case for Darwinian tumor evolution, Nature Medicine, vol.57, issue.4, pp.344-350, 2014. ,
DOI : 10.1038/nature10762
and high resolution melting PCR assays for the detection of KRAS somatic Bibliographie 186 mutations in formalin-fixed paraffin embedded colorectal carcinomas, Virchows Arch, vol.462, issue.3, pp.329-364, 2013. ,
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP, Proceedings of the National Academy of Sciences, vol.105, issue.6, pp.2070-2075, 2008. ,
DOI : 10.1073/pnas.0709662105
R??le du laboratoire d???anatomie pathologique dans l???approche pr??-analytique des examens de biologie mol??culaire r??alis??s en pathologie tumorale, Annales de Pathologie, vol.30, issue.2, pp.85-93, 2010. ,
DOI : 10.1016/j.annpat.2010.03.003
The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients, British Journal of Cancer, vol.26, issue.10, pp.1519-1542, 2010. ,
DOI : 10.1016/j.humpath.2007.04.008
Coexistence of two different mutations in codon 12 of the Kras gene in colorectal cancer: Report of a case supporting the concept of tumoral heterogeneity, Oncology Letters, vol.5, issue.5, pp.1741-1744, 2013. ,
DOI : 10.3892/ol.2013.1255
Evidence for the involvement of the Wnt 2 gene in human colorectal cancer, Oncogene, vol.12, issue.1, pp.153-161, 1996. ,
Downregulation of WIF-1 and Wnt5a in patients with colorectal carcinoma: clinical significance, Tumour Biol, vol.35, issue.8, pp.7975-82, 2014. ,
The potential of targeting Wnt/??-catenin in colon cancer, Expert Opinion on Therapeutic Targets, vol.162, issue.6, pp.611-616, 2014. ,
DOI : 10.1517/14728222.2014.906580
JAK/STAT/SOCS-signaling pathway and colon and rectal cancer, Molecular Carcinogenesis, vol.30, issue.2, pp.155-66, 2013. ,
DOI : 10.1002/mc.21841
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3430812
Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma, British Journal of Cancer, vol.40, issue.1, pp.138-184, 2013. ,
DOI : 10.1515/bc.2011.038
Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1alpha and STAT-3, Angiogenesis, vol.16, issue.4, pp.903-920, 2013. ,
IL-23 selectively promotes the metastasis of colorectal carcinoma cells with impaired Socs3 expression via the STAT5 pathway, Carcinogenesis, vol.35, issue.6, pp.1330-1370, 2014. ,
DOI : 10.1093/carcin/bgu017
AZD1480, a JAK inhibitor, inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling pathway, Oncology Reports, issue.10, p.20143477, 2014. ,
DOI : 10.3892/or.2014.3477
p38 MAP-Kinases pathway regulation, function and role in human diseases, Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol.1773, issue.8, pp.1358-75, 2007. ,
DOI : 10.1016/j.bbamcr.2007.03.010
P38MAPK is a major determinant of the balance between apoptosis and autophagy triggered by 5-fluorouracil: implication in resistance, Oncogene, vol.126, issue.9, pp.1073-85, 2012. ,
DOI : 10.1007/s004320050286
Blocking p38/ERK crosstalk affects colorectal cancer growth by inducing apoptosis in vitro and in preclinical mouse models, Cancer Letters, vol.324, issue.1, pp.98-108, 2012. ,
DOI : 10.1016/j.canlet.2012.05.006
Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis, International Journal of Cancer, vol.11, issue.5, pp.542-550, 2002. ,
DOI : 10.1002/ijc.10526
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer, Nature, vol.102, issue.7404, pp.532-538, 2012. ,
DOI : 10.1038/nature11156
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA, Nature Medicine, vol.2, issue.4, pp.430-435, 2014. ,
DOI : 10.1038/nm.3511
KRAS Genotypic Changes of Circulating Tumor Cells during Treatment of Patients with Metastatic Colorectal Cancer, PLoS ONE, vol.18, issue.8, p.2014, 2014. ,
DOI : 10.1371/journal.pone.0104902.t004
Prognostic relevance of minimal residual disease in colorectal cancer, World Journal of Gastroenterology, vol.20, issue.30, pp.10296-304, 2014. ,
DOI : 10.3748/wjg.v20.i30.10296
Downregulation of microRNA-100 correlates with tumor progression and poor prognosis in colorectal cancer, Medical Oncology, vol.31, issue.6, p.31235, 2014. ,
DOI : 10.1007/s12032-014-0235-x
Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy, Clinical Cancer Research, vol.20, issue.12, pp.3338-3385, 2014. ,
DOI : 10.1158/1078-0432.CCR-13-2750
The emergence of commercial genomics: analysis of the rise of a biotechnology subsector during the Human Genome Project, Genome Med, vol.5, issue.9, p.2013, 1990. ,
Differential Expression of miRNAs in Colorectal Cancer: Comparison of Paired Tumor Tissue and Adjacent Normal Mucosa Using High-Throughput Sequencing, PLoS ONE, vol.70, issue.4, p.17, 2012. ,
DOI : 10.1371/journal.pone.0034150.s007
Profiling Plasma MicroRNA in Nasopharyngeal Carcinoma with Deep Sequencing, Clinical Chemistry, vol.60, issue.5, pp.773-82, 2014. ,
DOI : 10.1373/clinchem.2013.214213
Cell Pairing Using Microwell Array Electrodes Based on Dielectrophoresis, Analytical Chemistry, vol.86, issue.14, pp.6818-6840, 2014. ,
DOI : 10.1021/ac5015996
abord développé des techniques pour le génotypage des gènes RAS et PIK3CA à partir d'échantillons de tumeurs colorectales fixées au formol et incluses en paraffine, puis dans un second temps, nous avons validé ces méthodes selon la norme ISO 15189, puis dans un dernier temps, nous avons étudié l'expression des phosphoprotéines en aval des récepteurs à l'EGF ainsi que les statuts mutationnels des gènes KRAS ,
associer la mesure de l'expression des phosphoprotéines de signalisation en aval d'EGFR, à l'analyse du statut mutationnel des gènes RAS, BRAF, PIK3CA pourrait présenter un intérêt dans la prédiction de la réponse aux thérapies anti-EGFR chez les patients atteints d'un cancer colorectal métastatique ,